Staining results from an Amsbio differentiation kit.

Amsbio Expands Skeletal Muscle Differentiation Kits for Reliable Myoblast Production

New kits deliver up to 70% MF20-positive myotubes without genetic intervention, supporting reproducible muscle research and drug discovery

Written byCraig Bradley
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00

Amsbio has introduced an expanded range of Skeletal Muscle Differentiation Kits designed to reproducibly convert pluripotent or embryonic stem cells into myoblasts with high regenerative potential. Using a simple 3-step process of media changes and cell passaging – these advanced kits can typically achieve 70% MF20-positive myotubes. The highly efficient protocol employed by the kit does not require genetic intervention or cell sorting, thereby saving valuable time in the lab.

Streamlined Stem Cell-to-Myoblast Differentiation Workflow

For lab managers overseeing stem cell research, consistency and efficiency are critical. Amsbio’s Skeletal Muscle Differentiation Kits are designed to work with all pluripotent stem cell lines, yielding a homogeneous and physiologically competent population of cells and cultures that are immediately suitable for screening and advanced drug discovery.

Key features of the expanded kit range include:

  • Simple 3-step differentiation protocol
  • Typically achieves 70% MF20-positive myotubes
  • No genetic intervention required
  • No cell sorting required
  • Compatible with all pluripotent stem cell lines
  • Produces homogeneous, physiologically competent cells

By eliminating the need for genetic manipulation or sorting, labs can reduce variability, shorten timelines, and optimize resource allocation—an important consideration for facilities balancing multiple research projects.

Flexible Supply and Custom Myoblast Generation Services

In addition to supplying Skeletal Muscle Differentiation Kits from stock, Amsbio also offers custom and outsourcing services for generating skeletal muscle myoblasts from a specific iPSC line of interest. This flexibility allows labs to integrate the service into virtually any workflow, whether rapid turnaround or application-specific cell production is required.

For lab managers seeking reproducible skeletal muscle models to support regenerative research, disease modeling, or drug screening programs, the expanded kit portfolio provides both scalability and technical simplicity.

For further information, visit https://www.amsbio.com/skeletal-muscle-differentiation or contact Amsbio at +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 or info@amsbio.com.

Add Lab Manager as a preferred source on Google

Add Lab Manager as a preferred Google source to see more of our trusted coverage.

About the Author

  • Person with beard in sweater against blank background.

    Craig Bradley BSc (Hons), MSc, has a strong academic background in human biology, cardiovascular sciences, and biomedical engineering. Since 2025, he has been working with LabX Media Group as a SEO Editor. Craig can be reached at cbradley@labx.com.

    View Full Profile

Related Topics

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - January/February 2026

How to Build Trust Into Every Lab Result

Applying the Six Cs Helps Labs Deliver Results Stakeholders Can Rely On

Lab Manager January/February 2026 Cover Image